Latest Hearing Health News

Audeara has reached a key milestone as its chip-level AI licensing partnership with Optek enters commercial production, receiving initial purchase orders worth about A$31,000. This validates Audeara’s scalable fee-per-chip licensing model and sets the stage for broader applications in audio and hearing health.

Audeara Ltd posted record FY26 cash receipts of $4.2 million and unaudited revenue of $4.44 million, driven by progress in AI audio licensing, exclusive assistive listening deals, and a large-scale Auracast deployment across retirement villages.

Audeara has locked in exclusive Australian rights to a customised assistive listening device from ShokzHear, aiming to tackle widespread listening challenges among schoolchildren through government-backed programs.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.